Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IGM Biosciences, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Demonstrated clinical benefit (SD, PR, or CR) on clinical trial protocol IGM-2323-001
There is no adequate alternative treatment available for the patient.
Provided consent to continue treatment on expanded access program.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to the first dose.
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures.
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive.
You may not be if
History of severe allergic or anaphylactic reactions to mAb (or recombinant antibody related fusion proteins).
Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of investigational product, or indicating patient would unlikely have potential benefit.
Pregnant, breastfeeding, or intending to become pregnant during the program or within 2 months after the final dose of imvotamab.
In the treating physician's judgement, the patient is unlikely to complete all procedures, including follow-up visits, or comply with the requirements for participation.
Vaccination with live virus vaccines during treatment and for 3 months following the last cycle of Imvotamab.
Clareo Health | Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
